Review

Secretory IgA: Linking microbes, maternal health, and infant health through human milk

Katherine Donald,[1,2,8] Charisse Petersen,[3,4,8] Stuart E. Turvey,[3,4] B. Brett Finlay,[1,2,5] and Meghan B. Azad[6,7,9,*]
[1]Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada
[2]Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada
[3]Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada
[4]British Columbia Children's Hospital, Vancouver, BC, Canada
[5]Department of Biochemistry, University of British Columbia, Vancouver, BC, Canada
[6]Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada
[7]Manitoba Interdisciplinary Lactation Centre (MILC), Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada
[8]These authors contributed equally
[9]Twitter: @MeghanAzad
*Correspondence: meghan.azad@umanitoba.ca
https://doi.org/10.1016/j.chom.2022.02.005

SUMMARY

Secretory immunoglobulin A (SIgA) in human milk plays a central role in complex maternal-infant interactions that influence long-term health outcomes. Governed by genetics and maternal microbial exposure, human milk SIgA shapes both the microbiota and immune system of infants. Historically, SIgA-microbe interactions have been challenging to unravel due to their dynamic and personalized nature, particularly during early life. Recent advances have helped to clarify how SIgA acts beyond simple pathogen clearance to help guide and constrain a healthy microbiota, promote tolerance, and influence immune system development. In this review, we highlight these new findings in the context of the critical early-life window and propose outstanding areas of study that will be key to harnessing the benefits of SIgA to support healthy immune development during infancy.

INTRODUCTION

Human milk is a complex mixture of nutrients, immunomodulatory factors, maternal cells, and microbes that function collectively to support healthy host-microbe interactions during infant development. As the prevalence of childhood allergic and metabolic disorders increased over the latter twentieth century and the role of microbiota in these pathologies gained increasing attention (Petersen and Turvey, 2020), it became abundantly clear that the maternal milk-infant relationship is critical to promoting healthy development on a population level (Bode et al., 2020). However, instead of revealing a clear and common mechanism driving this beneficial interaction, recent studies and technological advances have instead highlighted the diverse and personalized aspects of the maternal milk (Munblit et al., 2017; Nuzzi et al., 2021). Furthermore, this complexity is multilayered. In addition to maternal factors (e.g., genetics, parity, diet, and allergies) that contribute to differences in milk composition, many components change over the course of lactation, and each component seems capable of influencing infant development via interconnecting mechanistic pathways (Munblit et al., 2017). Thus, the dynamic nature of human milk makes it important but challenging to understand.

The first 3 months of life represent an important period of immune development during which microbial encounters can shape life-long immune health (Arrieta et al., 2015; Boutin et al., 2020; Al Nabhani and Eberl, 2020). Despite its intricacies, human milk is clearly a vital factor in microbiota establishment

and microbiota-mediated immune imprinting during this critical early-life window. To aid early colonization, human milk seeds the infant microbiota with a select consortium of microbes (Fehr et al., 2020; Moossavi et al., 2018) along with human milk oligosaccharides (HMOs), which act as a nutrient source to establish this niche (Bode, 2012). The microbial breakdown of these HMOs results in secondary metabolites that can then support healthy gut and immune cell development (Zuurveld et al., 2020). Human milk components also directly prime immune cells toward tolerant responses via cytokines (e.g., TGF-beta and IL-10), lactoferrin, and short-chain fatty acids that alter cellular differentiation and gene expression (Dawod and Marshall, 2019; Gridneva et al., 2021). Immune cell tolerance can be measured on a specific antigenic level as well as in relation to broader microbiota compositional fluctuations that occur early in life, as was evidenced in a mouse model demonstrating a rapid immune reaction toward the microbiota once animals were weaned (Al Nabhani et al., 2019; Verhasselt et al., 2008). Importantly, antibiotic exposure during this weaning-associated immune reaction can lead to aberrations in immune development (Al Nabhani et al., 2019), highlighting the importance of microbial colonization in early life. Although each of these mechanisms and milk components are broadly understood, their individual makeup and influence vary significantly among mother-infant dyads. For example, HMO and milk microbe compositions are highly personalized (Azad et al., 2018; Moossavi and Azad, 2020), and ranges of cytokine, immunoglobulin, and fatty-acid levels are highly variable (Munblit et al., 2017).

Figure 1. The dual role of SIgA in the gut: maintenance and clearance of targeted microbes

SIgA can carry out multiple functions upon binding to bacteria and other microbes in the gut. Dimeric IgA (dark blue) contains two IgA monomers linked by a J chain. The secretory component (light blue; SC) protects the SIgA against degradation and provides additional points for attachment to targets. Glycans (yellow) decorate the IgA dimer and the secretory component. SIgA can bind to targets through traditional Fab-dependent binding or through binding to the Fc region, glycans, or SC. Upon binding to its target, SIgA can aid in bacterial adherence to the epithelium, promote biofilm formation, provide a carbon source, and alter gene expression to reduce bacterial virulence. These mechanisms of action may aid in maintaining certain targeted species within the gut. SIgA binding can also neutralize pathogens, preventing their translocation and immune activation, and agglutinate fast-growing pathogens to promote their movement through the gastrointestinal tract. Thus, SIgA is also able to promote the clearance of potentially detrimental taxa.

Although many infant-mother interactions within and beyond human milk steer early-life development through multiple mechanisms, one of the most abundant human milk proteins, secretory immunoglobulin A (SIgA), has only recently been appreciated for its ability to regulate both microbial colonization and infant immune responses. IgA's impact on health has been historically restricted to infection defense via pathogen clearance; however, its function within the infant gut has now been broadened to include promoting colonization of beneficial microbes, maintaining microbial diversity, acting as a nutrient source, and regulating microbial genetic expression to modify metabolic outputs and virulence (Huus et al., 2021; Figure 1). In this way, the effects of SIgA are not limited to the microbiota but also influence immune cell development, resulting in tolerant host-microbe interactions within the gut. In this review, we will highlight the complexities of human milk SIgA and its role in establishing healthy host-microbe interactions in the infant gut.

SECRETORY IMMUNOGLOBULIN A: A KEY PLAYER IN THE GUT ENVIRONMENT

SIgA is the most abundant antibody in the human body and comprises two IgA monomers linked by a J chain and secreted via polymeric Ig receptor (pIgR). Upon translocation across the epithelium, pIgR donates a secretory component (SC) to the IgA dimer. The presence of SC differentiates secreted SIgA, found in human milk and at other mucosal sites, from dimeric IgA found in the serum. Unlike other antibodies, SIgA comes in two forms: T cell dependent SIgA, which is monoclonal and forms specific, high-affinity interactions, and T cell independent SIgA that is polyclonal and binds with less affinity (Bunker and Bendelac, 2018; Huus et al., 2021). SIgA can interact with bacteria in the gut through traditional Fab interactions, in the case of high-affinity IgA, or through nonspecific Fc interactions, or even through binding to the SC or associated glycan structures (Huus et al., 2021).

SIgA levels and targeting patterns vary tremendously between people and in response to environmental factors and infection. In healthy individuals, 10%–50% of the gut microbiota is bound by SIgA, and any one species may be targeted in one individual but not another (Palm et al., 2014; Sterlin et al., 2020). Host genetics and environmental factors contribute to this variation, and distinct patterns in IgA-targeting within populations can be identified. In order to study IgA-targeting patterns in feces and other mucosal secretions, the technique IgA-SEQ has been developed (Figure 2). This technique involves staining IgA-bound bacteria and then using fluorescence-associated cell sorting to sort bacteria into IgA+ and IgA− fractions. Cells in each fraction are then sequenced using 16S or shotgun sequencing, and an IgA index, which represents the relative proportion of bacteria targeted by IgA, is calculated for each strain (Jackson et al., 2021; Kau et al., 2015; Palm et al., 2014). Altered SIgA responses to the gut microbiota have been linked to several disease states, including inflammatory bowel disease (IBD), allergic disease, multiple sclerosis, metabolic disorders, and others (Huus et al., 2020a; Kukkonen et al., 2010; Palm et al., 2014; Pröbstel et al., 2020). In the case of IBD, increased overall coating of the gut microbiota, along with preferential coating of pathogenic bacteria in the gut, is associated with disease (Palm et al., 2014). Host nutrition and geographic location can also heavily influence IgA responses to the gut microbiota (Huus et al., 2020b). Whether these alterations represent a response to a disease-associated dysbiotic microbiota or an altered immune state which drives dysbiosis is not known, but the study of IgA-targeting patterns may provide a clearer diagnostic marker than microbiota sequencing alone. Although gut microbiota composition can provide insight into host health, the identification of IgA-targeted and untargeted species adds a layer of information about how the host is interacting with the microbes present.

The effects of antibody binding on bacteria and on the host are varied and complex (Figure 1). SIgA has been shown to act in the traditional antibody role of neutralizing and clearing pathogens. One mechanism for this clearance is agglutination, which involves SIgA-mediated clumping of bacteria. In the case of fast-growing bacterial cells, this clumping facilitates movement of the bacteria through and out of the intestine (Hoces et al.,

Figure 2. IgA-SEQ and its application to human milk IgA
IgA-SEQ is a widely used technique in the study of IgA-targeting patterns in fecal samples. The schematic details the technique and its potential application in human milk studies. A biological sample containing bacteria (feces, human milk, etc.) is used. Bacteria are isolated from the sample via centrifugation and filtration techniques. Cells are then stained using a nucleic acid stain, to identify bacteria, and a fluorescent antibody which binds the SIgA molecule. Stained bacteria are then sorted into IgA+ and IgA− fractions using fluorescence-associated cell sorting. The two fractions are then characterized by next-generation sequencing. Analysis of sequencing data involves generating an IgA index, which represents the ratio of bacterial abundance between IgA+ and IgA− fractions, for each genus or taxon present. When analyzing fecal or human milk samples from a group of individuals, IgA-targeting can be summarized for each taxa separately, enabling comparison of IgA-targeting between microbes and identification of patterns in IgA-targeting common to the group and/or different between groups. The use of this technique on human milk samples would aid in understanding of the roles and targeting patterns of SIgA.

2020). SIgA can also prevent translocation of pathogenic bacteria across the epithelium (Bollinger et al., 2003). Interestingly, SIgA also promotes the establishment of symbionts in the gut through supporting microbial adherence to epithelium and biofilm formation (Orndorff et al., 2004). Indeed, members of the microbiota have evolved to utilize SIgA, including *Bacteroides fragilis* that actively alters surface antigen expression to increase SIgA binding and enhance its colonization, as well as members of *Lachnospiraceae* that utilize superantigens to stimulate and bind SIgA (Bunker et al., 2019; Donaldson et al., 2018). Glycan structures on SIgA, which vary greatly between individuals, can also provide a carbon source for growing bacteria (Cao et al., 2014; Huang et al., 2015).

Multiple studies of individual SIgA-targeted strains have shown that antibody binding can also alter microbial gene expression. *Bacteroides thetaiotamicron*, a well-studied example of this, upregulates a gene cassette involved in interbacterial symbiosis in the gut in response to SIgA binding (Nakajima et al., 2018). The transfer of hybridoma "backpacks"

containing SIgA specific to *B. thetaiotamicron* was used to confirm the procolonization effects of SIgA on this microbe *in vivo*. Genes involved in virulence can also be downregulated in response to binding, facilitating host-microbe homeostasis in the gut (Bunker and Bendelac, 2018; Peterson et al., 2007; Tran et al., 2019). The mode of SIgA binding to a bacterium may also play a role in its effect. In one study, a monoclonal SIgA (W27) isolated from the mouse gut was found to bind to multiple microbes with varying strength (Okai et al., 2016). W27 inhibited growth of bacteria expressing the epitope targeted by the antibody Fab portion, although having no effect on bound bacteria which did not express the specific epitope. Antibody binding to these bacteria occurred presumably through Fab-independent interactions, indicating that stronger, Fab-dependent binding to bacteria may have a more dramatic hinderance effect on growth. Upon oral administration of W27, mice showed reduced susceptibility to colitis and an altered gut microbiota, supporting a potential therapeutic role for SIgA in the gut. In a study of host-microbe interactions associated with

malnutrition, binding through antibody glycan structures seemed to promote adherence of beneficial bacteria in the gut (Huus et al., 2020b). Thus, with its broad array of binding modes, targets, and functions, SIgA is a powerful and multifaceted modulator of the gut microbiota.

HUMAN MILK SIgA: THE LINK BETWEEN THE MATERNAL AND INFANT GUT

SIgA is abundant at all mucosal sites, including the mammary gland. SIgA is the dominant immunoglobulin in human milk, although IgM and IgG are also present. In colostrum, the milk produced in the first 5 days after birth, SIgA concentrations have been reported to range from 1.5 to 83.7 g/L (Mickleson and Moriarty, 1982). The levels decline after this period and continue to vary greatly between mothers (Mickleson and Moriarty, 1982; Rio-aige et al., 2021; Weaver et al., 1998). Many studies have quantified SIgA in human milk, but there is great heterogeneity in results due to differences in the quantification method, sample handling, collection techniques, low sample size, and general heterogeneity in IgA levels between individuals. A recent meta-analysis of these studies concluded that SIgA is highest in colostrum, lower in transition milk (5–15 days postgestation), and possibly more varied in mature milk (Rio-aige et al., 2021). The average SIgA concentrations were found to be 7.5 g/L in colostrum, and 1.6–2 g/L in transitional and mature milk. In contrast, IgM and IgG concentrations were primarily found to be lower than 1 g/L in milk at all post-gestation stages. Similar to intestinal SIgA, milk SIgA varies based on host genetics, environmental factors, and health. Several studies have shown stark differences in antibody levels between mothers from different geographic locations (Childs et al., 2017; Tomicić et al., 2010; Munblit et al., 2016).

In preparation for lactation, IgA-secreting plasma cells expressing CCR10 are recruited to the mammary gland by the chemokine CCL28 beginning during late pregnancy (Wilson and Butcher, 2004). Epithelial cells within the milk ducts express pIgR, enabling secretion of the full SIgA molecule directly into the milk. Upon weaning, CCL28 signaling and plasma cell accumulation decline rapidly in the mammary gland (Niimi et al., 2018). Plasma cells throughout the body, including the gut, express CCR10; however, gut-associated plasma cells have a higher propensity to home to mammary tissue. The gastrointestinal origins of breast tissue plasma cells were demonstrated by a study in which radioactively labeled gut mesenteric lymph node or peripheral lymph node cells were transferred to pregnant or virgin mice (Roux et al., 1977). A higher level of radioactivity was recovered in the mammary glands of pregnant mice receiving gut labeled plasma cells, and these cells produced higher levels of IgA that persisted from late pregnancy throughout lactation in these mice. A more recent study used a photoconvertible reporter mouse model to show that plasma cells migrate from the intestine to the mammary gland during late pregnancy (Ramanan et al., 2020). Furthermore, a comparison of the IgA repertoire at different body sites in mice showed great similarity between milk SIgA and intestinal SIgA (Lindner et al., 2015). Thus, maternal microbial encounters in the gut governs the quality and quantity of SIgA within human milk to help shape the infant microbiota.

SIgA in early life

Infants are not equipped with a fully developed immune system at birth, making them highly susceptible to infection and immune dysregulation as they enter and interact with a microbe-rich world (Torow et al., 2017). The first 3 months of life in particular represents a critical window for immune development. Host-microbe interactions that occur during this time contribute to immune imprinting, affecting life-long health (Al Nabhani and Eberl, 2020). Certain events during this critical period have been linked to later development of allergic and autoimmune disease, and the ways in which early-life host-microbe interactions influence immune development are still being uncovered (Boutin et al., 2020). Antibody responses are particularly lacking in the first several months of life. Adult antibody levels are not reached until after the first year of life, and serum IgA is extremely low or undetectable for the first 2 months of life (South et al., 1967; Weemaes et al., 2003), whereas fecal SIgA levels are high (Hibel and Schiltz, 2016). It is currently thought that IgA+ B cells are not produced by the infant until at least 4 weeks of age (Rognum et al., 1992). Thus, milk ingested by the infant is the primary source of SIgA during the vulnerable and vital early-life period. Milk SIgA plays many roles in the infant gut, including microbiota modulation, protection against pathogens, and dampening the infant immune response to the plethora of unfamiliar invaders (Atyeo and Alter, 2021). Defining the interactions between this maternal immune factor and the developing microbiota is thus an important step in understanding immune maturation.

Infants who do not receive human milk start producing SIgA in the intestine around 4 weeks of age (Neu and Walker, 2011). Breastfed infants show substantially increased SIgA levels in the feces for at least the first 3 months of life in comparison with formula-fed infants (Bridgman et al., 2016; Koutras and Vigorita, 1989). Interestingly, one study found that infant fecal SIgA levels at 6 months of age are higher in formula-fed infants compared with breastfed infants (Hibel and Schiltz, 2016). This may indicate premature SIgA production in response to the lack of maternal antibodies present, which aligns with the immune-dampening role of human milk immune factors in the infant gut (Hornef and Torow, 2020). It could also reflect compensation: breastfed infants may not need to produce as much SIgA because the maternal SIgA repertoire present is more efficient at targeting and modulating the gut microbiota.

Human milk SIgA and infection

The role of milk SIgA in infant health has been extensively studied in the context of infection and inflammation. Milk SIgA has been shown to target rotavirus, poliovirus, and other enteric pathogens previously encountered by the mother through infection or vaccination (Brandtzaeg, 2003; Patel et al., 2013; Wright et al., 2014). Influenza- and, more recently, SARS-CoV-2-specific IgA have also been found in the milk of immunized and recently recovered mothers (Nunes et al., 2017; Pace et al., 2021; Perl et al., 2021). These antibodies may protect the infant against infection while the immune system is still developing. One interesting analysis of the pathogen targeting abilities of milk from women across geographical regions displayed region-specific patterns in targeting, supporting the idea that human milk is tailored to the infant based on the maternal environment (McGuire et al., 2021). However,

Figure 3. Human milk SIgA and the infant gut microbiota
Plasma cells originating in the maternal intestine migrate to the mammary gland through circulation during late pregnancy and lactation. These cells produce IgA antibodies that are secreted into the human milk. Breastmilk SIgA is transferred to the infant through breastmilk feeding, along with human milk microbes (shown in pink), some of which are SIgA-bound. During birth and early life, microbes from the maternal gut (shown in blue) are transmitted to the infant gut. SIgA, the maternal gut flora, and human milk microbes from the mother work together to establish and maintain the infant gut community.

nonspecific SIgA interactions may confer protection as well, as studies of a Canadian birth cohort have shown that overall increased infant fecal SIgA levels are associated with breast-feeding and reduced *Clostridium difficile* colonization (Bridgman et al., 2016).

SIgA in preterm delivery and necrotizing enterocolitis (NEC)

Preterm delivery affects all arms of the immune system and puts infants at increased risk for infection and chronic inflammatory disease (Melville and Moss, 2013). Necrotizing enterocolitis (NEC) is a dangerous gastrointestinal disease that is common among premature infants (Neu and Walker, 2011). It involves an inflammatory response to the gut microbiota and is associated with reduced microbiota diversity and overrepresentation of *Enterobacteriaceae* (Pammi et al., 2017). It is unclear whether preterm milk has an altered SIgA composition. One study showed increased SIgA levels following preterm birth (Koenig et al., 2005), whereas others show no difference (Trend et al., 2016), although survival of secretory immunoglobulins in the digestive tract of preterm infants may be increased (Demers-Mathieu et al., 2018). It is clear that breastfeeding, and SIgA in human milk specifically, protects the preterm infant against infections and NEC (Neu and Walker, 2011). However, the mother's own milk may not always be available to the preterm infant, depending on the gestational stage at delivery and maternal health status, and other factors. Many of these infants receive pasteurized human donor milk, which maintains partial immunological activity, including from SIgA (Irazusta et al., 2020). One clinical trial from 1988 showed that administration of an oral immunoglobulin supplement containing IgA and IgG protects against NEC in preterm infants not receiving human milk (Eibl et al., 1988). IgA supplementation has not been widely pursued since this small study was completed, perhaps on account of difficulty in IgA manufacturing and a lack of knowledge related to IgA specificity in the gut. However, recent characterization of IgA's multifaceted role support that this antibody should be further pursued for its potential therapeutic and preventative effects.

More recent studies have clarified the roles of SIgA in preventing NEC. Infants who developed NEC showed reduced SIgA targeting of the gut microbiota compared with healthy, age-matched controls (Gopalakrishna et al., 2019). The changes associated with NEC seemed to be driven by a reduction in SIgA targeting of *Enterobacteriaceae*, enabling their overgrowth in the gut. In comparison, IgG and IgM did not play a detectable role. Supporting this association, a mouse model of NEC in which offspring fed by IgA-deficient dams was more susceptible to disease (Gopalakrishna et al., 2019). Notably, the outcomes of the pups given SIgA deficient milk were indistinguishable from formula-fed pups. The effects of SIgA on NEC susceptibility and pathogenesis therefore support the important role of this antibody in modulating the gut microbiota and preventing inflammation in early life.

HUMAN MILK SIgA AND THE DEVELOPING GUT MICROBIOTA

Human milk is the primary source of antibodies in the infant intestine, and SIgA is gaining more attention for its role in modulating the early-life gut microbiota (Figure 3). It is clear that this antibody plays an important role in protecting the underdeveloped immune and mucosal tissue from pathogens and inflammation, but it likely also plays an even more complex role in gut microbiota development and host-microbe symbiosis. This is an exciting hypothesis that warrants further study, as changes in the gut microbiota during the first few months have been shown to affect life-long host health (Boutin et al., 2020; Nino et al., 2021). Studies of human milk SIgA may contribute to a better understanding of the "microflora hypothesis" which postulates that microbial exposure in infancy affect the developing immune system (Penders et al., 2007; Wold, 1998). Reduced diversity and a loss of specific taxa in the infant gut are associated with later development of several chronic diseases, but the reasons for microbiota differences between infants and the mechanisms driving microbial maintenance and adherence in the gut are not fully elucidated (Bisgaard et al., 2011; Nino et al., 2021; Petersen and Turvey, 2020). SIgA is a promising candidate factor in shaping a healthy gut microbiota, and human and animal studies are just beginning to uncover the interactions between milk SIgA and beneficial members of the gut microbiota. Other

human milk components, such as HMOs, microbes, and cytokines, have been studied for their effects on the infant gut, but SIgA is only starting to be appreciated for its contribution to breastmilk's role in early-life microbiota development.

At 10 days of age, 80% of the gut microbiota is bound by SIgA in breastfed infants (Gopalakrishna et al., 2019). Targeting decreases slightly over the course of infancy, to 50% at 1 month and 30% at 12 months of age, but varies significantly between infants (Dzidic et al., 2017). *Bifidobacterium* and *Enterobacteriaceae* are enriched in IgA+ fractions obtained from infant feces and are both positively associated with fecal IgA levels (Janzon et al., 2019). *Bifidobacterium* species are the most well-characterized members of the infant gut microbiota and are known to be favored by the prebiotic content of human milk (Henrick et al., 2021). Certain strains of Bifidobacteria also have numerous beneficial effects on infant development, and their abundance has been linked to increased immunoregulatory responses, protection against enteropathogens, and reduced allergic disease susceptibility (Fukuda et al., 2011; Henrick et al., 2021; Kalliomäki et al., 2001). Although HMOs are utilized by some Bifidobacteria, human milk SIgA may also play a role in the establishment of Bifidobacterial communities in the infant gut (Chichlowski et al., 2012; Henrick et al., 2021). As described above, SIgA has been shown to promote colonization of certain commensals in the intestine, but a procolonization mechanism of SIgA-Bifidobacteria interactions has yet to be explored. Through clearance and inhibition of other species, SIgA might also indirectly provide a niche for Bifidobacteria and other beneficial species in the infant gut. This is supported by dysbiosis associated with both SIgA deficiency and formula feeding (Catanzaro et al., 2019; Gopalakrishna and Hand, 2020). Increased levels of *Enterobacteriaceae* are associated with formula feeding (Kim and Yi, 2020), and a loss of IgA-targeting of this family was linked to overgrowth and development of NEC (Gopalakrishna et al., 2019). Future studies should focus in on individual bacterial taxa and the effect that maternal SIgA has on them in the gut.

In vivo mouse studies of milk SIgA support its role in shaping the gut microbiota and mucosal immunity early in life. In one informative study, a transgenic mouse lacking pIgR was used to isolate the influence of maternal milk SIgA from that of host endogenous SIgA produced by offspring. The pIgR-deficient mouse (pIgR(−/−)) is unable to secrete IgA across the mucosal epithelium but produces normal levels of serum IgA, whereas pIgR(+/−) mice secrete normal levels of IgA into the intestine and mammary gland. After crossing a pIgR(−/−) female with a pIgR(+/−) male, Rogier et al. studied several alterations associated with maternal SIgA specifically (Rogier et al., 2014). All pups were nursed by their biological pIgR(−/−) mother, and half of them inherited the functional pIgR gene through the cross; however, none of them received SIgA through milk. Pups that did not receive SIgA through nursing displayed increased bacterial translocation across the epithelium, as demonstrated by increased culturable bacteria in harvested mesenteric lymph nodes. These mice also displayed distinct shifts in microbiota composition which lasted through adulthood, even after endogenous SIgA production in pIgR(+/−) offspring began. This indicates that early-life SIgA-microbe interactions have a lasting impact on the gut microbiota. A lack of milk SIgA was also associated with increased expression of genes related to intestinal inflammatory disease (Rogier et al., 2014). The breeding scheme in this study provided a wealth of information about milk SIgA in the neonatal gut and should be utilized in the future to look specifically at the role of milk SIgA in disease models and other phenotypes.

Human milk SIgA and milk microbes

SIgA interacts with the microbes found in human milk and may facilitate their maintenance in the infant gut. This is a new topic of interest, and only a few publications include analysis of the targeting patterns of SIgA within human milk. Based on the limited available data, approximately 40% of the human milk microbiota is IgA-bound (Dzidic et al., 2020). *Bifidobacteria*, *Streptococcus*, and *Lactobacillus* are IgA-targeted in the maternal gut, milk, and infant intestine, suggesting that SIgA aids in the mother-to-infant transfer of microbes. A phylogenetic analysis of *Bifidobacterium longum* strains show identical strains in mother-infant dyads, suggesting direct vertical transmission of this species, although the role of SIgA in this transfer was not directly studied (Meyer et al., 2019). The mechanism for transmission of microbes from the maternal gut and environment to the infant is not well understood (Wang et al., 2020), but SIgA may mediate transfer and maintenance of specific strains in the infant. IgA-SEQ has been developed and well utilized in adult gut microbiota studies and can be used to further characterize the host-microbe interactions occurring within human milk (Figure 2).

IgA-MICROBIOTA INTERACTIONS, THE DEVELOPING IMMUNE SYSTEM, AND ALLERGIC DISEASE

In addition to providing passive immunity, breastfeeding has been shown to dampen immune responses early in life, preventing inflammation and overactive responses to unfamiliar microbes throughout the body. In this way, human milk can be thought of as the "training wheels" for the developing immune system. Upon weaning, the gut microbiota increases in diversity and shifts toward a more adult-like state. In mice, a rapid increase in various immune cell populations accompanies this shift (Dogra et al., 2021; Al Nabhani and Eberl, 2020). Perhaps counterintuitively, maintaining an "immature state" of intestinal host-microbe interactions through breastfeeding actually seems to benefit the infant, protecting against later development of chronic disease (Knoop et al., 2018). Studies suggest that immune system dampening in this early stage of life promotes a more balanced and regulatory immune response to the environment as the infant matures (Al Nabhani et al., 2019).

In vivo and epidemiological studies suggest that SIgA may play a role in the phenomenon of immune dampening. When pIgR+/− mice, which produce their own SIgA, are fed by pIgR−/− dams, which do not secrete IgA, they begin to produce endogenous SIgA prematurely and are more prone a mouse model of colitis (Harris et al., 2021). Mice fed by pIgR−/+ dams with normal levels of milk SIgA show increased expression of genes involved in maintenance of the epithelial layer in comparison with mice fed by pIgR−/− dams, suggesting that early-life milk SIgA drives changes in the mucosal epithelium (Rogier et al., 2014). Maternally transferred IgA also mediates regulatory T cell homeostasis in the developing gut. Through cross-fostering of mouse pups by genetically different dams, Ramanan

et al. showed that milk SIgA affects RORγt Treg cell proportions in the neonate and that the set-point established during the early post-birth period impacts life-long T cell levels (Ramanan et al., 2020). These effects persisted through multiple generations, supporting the long-term importance of human milk SIgA in early life. Furthermore, SIgA has also been demonstrated to coordinate with maternally acquired IgG to promote tolerant T cell responses within the gut (Koch et al., 2016). Thus, SIgA provides a mode of nongenetic inheritance from mother to infant that occurs exclusively during the early infancy window.

Human studies also suggest that milk IgA postpones infant immune plasma cell development. As mentioned previously, formula-fed infants have increased SIgA responses at 6 months of age in comparison with breastfed infants, potentially representing an overactive immune response to the gut microbiota in the absence of maternal SIgA's dampening effects (Hibel and Schiltz, 2016). At the same time, formula-fed infants display a more mature gut microbiota earlier than breastfed infants (Ma et al., 2020), and the relative contribution of SIgA has not been disentangled from the effects of differences in microbiota composition alone on host health. Gut microbiota diversity and IgA repertoire diversity are dependent on each other, as increases in one lead to increases in the other. It is likely that the early spike in diversity observed in the formula-fed infant gut drives the relative rise in SIgA levels, although whether the premature activation of infant plasma cells affects the antibody efficiency or sensitivity is not known.

Human milk SIgA and its interactions with gut microbiota may also play a role in allergy susceptibility. Rates of allergic disease have increased markedly over the past 2–3 decades, and allergies have been linked to the "microflora hypothesis" described earlier (Boutin et al., 2020; Petersen and Turvey, 2020; Sbihi et al., 2019). Whether breastfeeding protects against allergies is not entirely clear, which may be due to the great heterogeneity that exists in human milk composition among mothers (Nuzzi et al., 2021; Oddy, 2017). Human milk SIgA levels and targeting patterns vary among mothers and can be influenced by genetics and microbial experience. Despite the variability, fecal SIgA levels seem to be reduced in infants who develop allergies (Kukkonen et al., 2010; Orivuori et al., 2014). Furthermore, at one month of age, when fecal SIgA is likely almost entirely of maternal origin, infants who go on to develop allergies show altered IgA-targeting of several intestinal taxa (Dzidic et al., 2017). Since human milk SIgA originates in the mother's intestine, differences in the SIgA repertoire are likely explained by differences in the gut microbiota among mothers. Therefore, as beneficial IgA-targeted species are identified, probiotic supplementation that drives intestinal IgA responses to these species in the mother could potentially be used to improve and diversify the IgA transmitted to the infant.

CONCLUSIONS AND FUTURE DIRECTIONS

Intestinal secretory IgA has been extensively studied for its role in modulating the microbiota, clearing pathogens, and impacting systemic host health. IgA-SEQ analyses have shed light on the great variation in targeting patterns between healthy individuals, as well as the specific alterations in IgA activity associated with several disease states. Human milk SIgA represents an exciting

new domain for understanding the close interaction between the host and the gut microbiota during the critical and vulnerable period of infancy. So far, research has shown that human milk SIgA originates in the maternal intestine and varies greatly among mothers. Breastfeeding enables antibody-mediated protection of the infant against enteropathogens and NEC and can have multigenerational effects. Milk SIgA also influences the developing gut microbiota (e.g., via pathogen exclusion, aiding early colonizers, and niche promotion) and can thus impact life-long health and immunity, and a limited set of studies suggest that SIgA may target milk microbes, affecting their ability to colonize the infant gut.

Although the origins of human milk SIgA and its ability to clear pathogens are well established, its capacity to promote beneficial taxa and drive immune and microbiota maturation are still far from understood. Future studies of the human milk "immunoglobulin-ome" should seek to not only quantify SIgA but also to identify its targets within the milk itself and upon delivery to the infant gut. It is clear that SIgA specificity may be more important than the overall amount of SIgA present (Dzidic et al., 2017; Palm et al., 2014). Further, in vivo studies using mouse models of IgA-deficiency and cross-fostering schemes should be used to understand the role of maternal SIgA, in addition to endogenously produced IgA, in various chronic diseases and inflammatory phenotypes. In vitro studies used to study IgA-mediated biofilm formation, adherence, and changes in gene expression can serve as models in the study of milk SIgA interactions with microbes important in the infant gut, such as species within the families Bifidobacteriaceae and Enterobacteriaceae. Human milk is rich in immune and nutritional components adapted to the infant's needs, but it differs greatly in composition among women and across populations. Given the life-long impact of early-life gut microbiota development patterns, understanding the contribution of milk SIgA to gut homeostasis in the infant is critical. Future research in this field may guide improvements in infant feeding practices and products, maternal probiotic supplementation, and preventative health interventions.

the Four Year Fellowship Tuition Award, President's Academic Excellence Initiative PhD Award, and International Tuition Award at UBC.

REFERENCES

Al Nabhani, Z., Dulauroy, S., Marques, R., Cousu, C., Al Bounny, S., Déjardin, F., Sparwasser, T., Bérard, M., Cerf-Bensussan, N., and Eberl, G. (2019). A weaning reaction to microbiota is required for resistance to immunopathologies in the adult. Immunity 50, 1276–1288.e5.

Al Nabhani, Z., and Eberl, G. (2020). Imprinting of the immune system by the microbiota early in life. Mucosal Immunol 13, 183–189.

Arrieta, M.-C., Stiemsma, L.T., Dimitriu, P.A., Thorson, L., Russell, S., Yurist-Doutsch, S., Kuzeljevic, B., Gold, M.J., Britton, H.M., Lefebvre, D.L., et al. (2015). Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med. 7, 307ra152.

Atyeo, C., and Alter, G. (2021). The multifaceted roles of breast milk antibodies. Cell 184, 1486–1499.

Azad, M.B., Robertson, B., Atakora, F., Becker, A.B., Subbarao, P., Moraes, T.J., Mandhane, P.J., Turvey, S.E., Lefebvre, D.L., Sears, M.R., and Bode, L. (2018). Human milk oligosaccharide concentrations are associated with multiple fixed and modifiable maternal characteristics, environmental factors, and feeding practices. J. Nutr. 148, 1733–1742.

Bisgaard, H., Li, N., Bonnelykke, K., Chawes, B.L.K., Skov, T., Paludan-Müller, G., Stokholm, J., Smith, B., and Krogfelt, K.A. (2011). Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J. Allergy Clin. Immunol. 128, 646–652.e1-5.

Bode, L. (2012). Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22, 1147–1162.

Bode, L., Raman, A.S., Murch, S.H., Rollins, N.C., and Gordon, J.I. (2020). Understanding the mother-breastmilk-infant "triad". Science 367, 1070–1072.

Bollinger, R.R., Everett, M.L., Palestrant, D., Love, S.D., Lin, S.S., and Parker, W. (2003). Human secretory immunoglobulin A may contribute to biofilm formation in the gut. Immunology 109, 580–587.

Boutin, R.C.T., Sbihi, H., Dsouza, M., Malhotra, R., Petersen, C., Dai, D., Sears, M.R., Moraes, T.J., Becker, A.B., Azad, M.B., et al. (2020). Mining the infant gut microbiota for therapeutic targets against atopic disease. Allergy 75, 2065–2068.

Brandtzaeg, P. (2003). Mucosal immunity: integration between mother and the breast-fed infant. Vaccine 21, 3382–3388.

Bridgman, S.L., Konya, T., Azad, M.B., Guttman, D.S., Sears, M.R., Becker, A.B., Turvey, S.E., Mandhane, P.J., Subbarao, P., et al.; CHILD Study Investigators (2016). High fecal IgA is associated with reduced Clostridium difficile colonization in infants. Microbes Infect 18, 543–549.

Bunker, J.J., and Bendelac, A. (2018). IgA responses to microbiota. Immunity 49, 211–224.

Bunker, J.J., Drees, C., Watson, A.R., Plunkett, C.H., Nagler, C.R., Schneewind, O., Eren, A.M., and Bendelac, A. (2019). B cell superantigens in the human intestinal microbiota. Sci. Transl. Med. 11, eaau9356.

Cao, Y., Rocha, E.R., and Smith, C.J. (2014). Efficient utilization of complex N-linked glycans is a selective advantage for Bacteroides fragilis in extraintestinal infections. Proc. Natl. Acad. Sci. USA 111, 12901–12906.

Catanzaro, J.R., Strauss, J.D., Bielecka, A., Porto, A.F., Lobo, F.M., Urban, A., Schofield, W.B., and Palm, N.W. (2019). IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM. Sci. Rep. 9, 13574.

Chichlowski, M., de Lartigue, G., German, J.B., Raybould, H.E., and Mills, D.A. (2012). Bifidobacteria isolated from infants and cultured on human milk oligo-

saccharides affect intestinal epithelial function. J. Pediatr. Gastroenterol. Nutr. 55, 321–327.

Childs, C.E., Espinosa-Martos, I., Garcia-Carrel, C., Manzano, S., McGuire, M.K., Meehan, C.L., McGuire, M.A., Williams, J.E., Foster, J.A., Sellen, D.W., et al. (2017). What's normal? Immune profiling of human milk from healthy women living in different geographical and socioeconomic settings. Front. Immunol. 8, 1–17.

Dawod, B., and Marshall, J.S. (2019). Cytokines and soluble receptors in breast milk as enhancers of oral tolerance development. Front. Immunol. 10, 16.

Demers-Mathieu, V., Underwood, M.A., Beverly, R.L., Nielsen, S.D., and Dallas, D.C. (2018). Comparison of human milk immunoglobulin survival during gastric digestion between preterm and term infants. Nutrients 10, 631.

Dogra, S.K., Kwong Chung, C., Wang, D., Sakwinska, O., Colombo Mottaz, S., and Sprenger, N. (2021). Nurturing the early life gut microbiome and immune maturation for long term health. Microorganisms 9, 2110.

Donaldson, G.P., Ladinsky, M.S., Yu, K.B., Sanders, J.G., Yoo, B.B., Chou, W.-C., Conner, M.E., Earl, A.M., Knight, R., Bjorkman, P.J., and Mazmanian, S.K. (2018). Gut microbiota utilize immunoglobulin A for mucosal colonization. Science 360, 795–800.

Dzidic, M., Abrahamsson, T.R., Artacho, A., Björkstén, B., Collado, M.C., Mira, A., and Jenmalm, M.C. (2017). Aberrant IgA responses to the gut microbiota during infancy precede asthma and allergy development. J. Allergy Clin. Immunol. 139, 1017–1025.e14.

Dzidic, M., Mira, A., Artacho, A., Abrahamsson, T.R., Jenmalm, M.C., and Collado, M.C. (2020). Allergy development is associated with consumption of breastmilk with a reduced microbial richness in the first month of life. Pediatr. Allergy Immunol. 31, 250–257.

Eibl, M.M., Wolf, H.M., Fürnkranz, H., and Rosenkranz, A. (1988). Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N. Engl. J. Med. 319, 1–7.

Fehr, K., Moossavi, S., Sbihi, H., Boutin, R.C.T., Bode, L., Robertson, B., Yonemitsu, C., Field, C.J., Becker, A.B., Mandhane, P.J., et al. (2020). Breastmilk feeding practices are associated with the co-occurrence of bacteria in mothers' milk and the infant gut: the CHILD cohort study. Cell Host Microbe 28, 285–297.e4.

Fukuda, S., Toh, H., Hase, K., Oshima, K., Nakanishi, Y., Yoshimura, K., Tobe, T., Clarke, J.M., Topping, D.L., Suzuki, T., et al. (2011). Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469, 543–547.

Gopalakrishna, K.P., and Hand, T.W. (2020). Influence of maternal milk on the neonatal intestinal microbiome. Nutrients 12, 823.

Gopalakrishna, K.P., Macadangdang, B.R., Rogers, M.B., Tometich, J.T., Firek, B.A., Baker, R., Ji, J., Burr, A.H.P., Ma, C., Good, M., et al. (2019). Maternal IgA protects against the development of necrotizing enterocolitis in preterm infants. Nat. Med. 25, 1110–1115.

Gridneva, Z., Lai, C.T., Rea, A., Tie, W.J., Ward, L.C., Murray, K., Hartmann, P.E., and Geddes, D.T. (2021). Human milk immunomodulatory proteins are related to development of infant body composition during the first year of lactation. Pediatr. Res. 89, 911–921.

Harris, N.L., Spoerri, I., Schopfer, J.F., Nembrini, C., Merky, P., Massacand, J., Urban, J.F., Jr., Lamarre, A., Burki, K., Odermatt, B., et al. (2021). Mechanisms of neonatal mucosal antibody protection. J. Immunol. 177, 6256–6262.

Henrick, B.M., Rodriguez, L., Lakshmikanth, T., Pou, C., Henckel, E., Arzoomand, A., Olin, A., Wang, J., Mikes, J., Tan, Z., et al. (2021). Bifidobacteria-mediated immune system imprinting early in life. Cell 184, 3884–3898.e11.

Hibel, L.C., and Schiltz, H. (2016). Maternal and infant secretory immunoglobulin A across the peripartum period. J. Hum. Lact. 32, NP44–NP51.

Hoces, D., Arnoldini, M., Diard, M., Loverdo, C., and Slack, E. (2020). Growing, evolving and sticking in a flowing environment: understanding IgA interactions with bacteria in the gut. Immunology 159, 52–62.

Hornef, M.W., and Torow, N. (2020). 'Layered immunity' and the 'neonatal window of opportunity' – timed succession of non-redundant phases to establish mucosal host–microbial homeostasis after birth. Immunology 159, 15–25.

Huang, J., Guerrero, A., Parker, E., Strum, J.S., Smilowitz, J.T., German, J.B., and Lebrilla, C.B. (2015). Site-specific glycosylation of secretory immunoglobulin A from human colostrum. Journal of proteome research 14 (3), 1335–1349.

Huus, K.E., Bauer, K.C., Brown, E.M., Bozorgmehr, T., Woodward, S.E., Serapio-Palacios, A., Boutin, R.C.T., Petersen, C., and Finlay, B.B. (2020b). Commensal bacteria modulate immunoglobulin A binding in response to host nutrition. Cell Host Microbe 27, 909–921.e5.

Huus, K.E., Petersen, C., and Finlay, B.B. (2021). Diversity and dynamism of IgA–microbiota interactions. Nat. Rev. Immunol. 21, 514–525.

Huus, K.E., Rodriguez-Pozo, A., Kapel, N., Nestoret, A., Habib, A., Dede, M., Manges, A., Collard, J.M., Sansonetti, P.J., Vonaesch, P., et al. (2020a). Immunoglobulin recognition of fecal bacteria in stunted and non-stunted children : findings from the Afribiota study. Microbiome 8, 113.

Irazusta, A., Rodríguez-Camejo, C., Jorcin, S., Puyol, A., Fazio, L., Arias, F., Castro, M., Hernández, A., and López-Pedemonte, T. (2020). High-pressure homogenization and high hydrostatic pressure processing of human milk: preservation of immunological components for human milk banks. J. Dairy Sci. 103, 5978–5991.

Jackson, M.A., Pearson, C., Ilott, N.E., Huus, K.E., Hegazy, A.N., Webber, J., Finlay, B.B., Macpherson, A.J., Powrie, F., and Lam, L.H. (2021). Accurate identification and quantification of commensal microbiota bound by host immunoglobulins. Microbiome 9, 33.

Janzon, A., Goodrich, J.K., Koren, O., Waters, J.L., and Ley, R.E. (2019). Interactions between the gut microbiome and mucosal immunoglobulins A, M, and G in the developing infant gut. mSystems 4, 1–17.

Kalliomäki, M., Kirjavainen, P., Eerola, E., Kero, P., Salminen, S., and Isolauri, E. (2001). Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J. Allergy Clin. Immunol. 107, 129–134.

Kau, A.L., Planer, J.D., Liu, J., Rao, S., Yatsunenko, T., Trehan, I., Manary, M.J., Liu, T.-C., Stappenbeck, T.S., Maleta, K.M., et al. (2015). Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. Sci. Transl. Med. 7, 276ra24.

Kim, S.Y., and Yi, D.Y. (2020). Analysis of the human breast milk microbiome and bacterial extracellular vesicles in healthy mothers. Exp. Mol. Med. 52, 1288–1297.

Knoop, K.A., Gustafsson, J.K., Mcdonald, K.G., Kulkarni, D., Paige, E., Mccrate, S., Kim, D., Hsieh, C.-S., Hogan, S.P., Elson, C.O., et al. (2018). Microbial antigen encounter During a pre-weaning interval is critical for tolerance to gut bacteria. Sci. Immunol. 2, eaao1314.

Koch, M.A., Reiner, G.L., Lugo, K.A., Kreuk, L.S.M., Stanbery, A.G., Ansaldo, E., Seher, T.D., Ludington, W.B., and Barton, G.M. (2016). Maternal IgG and IgA antibodies dampen mucosal T Helper cell responses in early life. Cell 165, 827–841.

Koenig, A., de Albuquerque Diniz, E.M., Barbosa, S.F., and Vaz, F.A. (2005). Immunologic factors in human milk ilthe effects of gestational age and pasteurization. J. Hum. Lact. 21, 439–443.

Koutras, A.K., and Vigorita, V.J. (1989). Fecal secretory immunoglobulin A in breast milk Versus formula feeding in early infancy. J. Pediatr. Gastroenterol. Nutr. 9, 58–61.

Kukkonen, K., Kuitunen, M., Haahtela, T., Korpela, R., Poussa, T., and Savilahti, E. (2010). High intestinal IgA associates with reduced risk of IgE-associated allergic diseases. Pediatr. Allergy Immunol. 21, 67–73.

Lindner, C., Thomsen, I., Wahl, B., Ugur, M., Sethi, M.K., Friedrichsen, M., Smoczek, A., Ott, S., Baumann, U., Suerbaum, S., et al. (2015). Diversification of memory B cells drives the continuous adaptation of secretory antibodies to gut microbiota. Nat. Immunol. 16, 880–888.

Ma, J., Li, Z., Zhang, W., Zhang, C., Zhang, Y., Mei, H., Zhuo, N., Wang, H., Wang, L., and Wu, D. (2020). Comparison of gut microbiota in exclusively breast-fed and formula-fed babies: a study of 91 term infants. Sci. Rep. 10, 15792.

McGuire, M.K., Randall, A.Z., Seppo, A.E., Järvinen, K.M., Meehan, C.L., Gindola, D., Williams, J.E., Sellen, D.W., Kamau-Mbuthia, E.W., Kamundia, E.W., et al. (2021). Multipathogen analysis of IgA and IgG antigen specificity for selected pathogens in milk produced by women from diverse geographical regions: the INSPIRE study. Front. Immunol. 11, 614372.

Melville, J.M., and Moss, T.J.M. (2013). The immune consequences of preterm birth. Front. Neurosci. 7, 79.

Meyer, K.M., Prince, A.L., and Aagaard, K.M. (2019). Maternal IgA targets commensal microbiota in breast milk and the maternal and infant gut microbiomes. Am. J. Obstet. Gynecol. 220, S604–S605.

Mickleson, K.N., and Moriarty, K.M. (1982). Immunoglobulin levels in human colostrum and milk. J. Pediatr. Gastroenterol. Nutr. 1, 381–384.

Moossavi, S., and Azad, M.B. (2020). Origins of human milk microbiota: new evidence and arising questions. Gut Microbes 12, 1667722.

Moossavi, S., Miliku, K., Sepehri, S., Khafipour, E., and Azad, M.B. (2018). The prebiotic and probiotic properties of human milk: implications for infant immune development and pediatric asthma. Front. Pediatr. 6, 197.

Munblit, D., Peroni, D.G., Boix-Amorós, A., Hsu, P.S., Van't Land, B., Gay, M.C.L., Kolotilina, A., Skevaki, C., Boyle, R.J., Collado, M.C., et al. (2017). Human milk and allergic diseases: an unsolved puzzle. Nutrients 9, 894.

Munblit, D., Sheth, S., Abrol, P., Treneva, M., Peroni, D.G., Chow, L.-Y., Boner, A.L., Pampura, A., Warner, J.O., and Boyle, R.J. (2016). Exposures influencing total IgA level in colostrum. J. Dev. Orig. Health Dis. 7, 61–67.

Nakajima, A., Vogelzang, A., Maruya, M., Miyajima, M., Murata, M., Son, A., Kuwahara, T., Tsuruyama, T., Yamada, S., Matsuura, M., et al. (2018). IgA regulates the composition and metabolic function of gut microbiota by promoting symbiosis between bacteria. J. Exp. Med. 215, 2019–2034.

Neu, J., and Walker, W.A. (2011). Necrotizing enterocolitis. N. Engl. J. Med. 364, 255–264.

Niimi, K., Usami, K., Fujita, Y., Abe, M., Furukawa, M., Suyama, Y., Sakai, Y., Kamioka, M., Shibata, N., Park, E.J., et al. (2018). Development of immune and microbial environments is independently regulated in the mammary gland. Mucosal Immunol 11, 643–653.

Nino, G., Rodriguez-Martinez, C.E., and Gutierrez, M.J. (2021). Early microbial-immune interactions and innate immune training of the respiratory system during health and disease. Children (Basel) 8, 413.

Nunes, M.C., Cutland, C.L., Jones, S., Downs, S., Weinberg, A., Ortiz, J.R., Neuzil, K.M., Simões, E.A.F., Klugman, K.P., and Madhi, S.A. (2017). Efficacy of maternal influenza vaccination against all-cause lower respiratory tract infection hospitalizations in young infants: results from a randomized controlled trial. Clin. Infect. Dis. 65, 1066–1071.

Nuzzi, G., di Cicco, M.E., and Peroni, D.G. (2021). Breastfeeding and allergic diseases: What's new? Children (Basel) 8, 330.

Oddy, W.H. (2017). Breastfeeding, childhood asthma, and allergic disease. Ann. Nutr. Metab. 70 (Suppl 2), 26–36.

Okai, S., Usui, F., Yokota, S., Hori-I, Y., Hasegawa, M., Nakamura, T., Kurosawa, M., Okada, S., Yamamoto, K., Nishiyama, E., et al. (2016). High-affinity monoclonal IgA regulates gut microbiota and prevents colitis in mice. Nat. Microbiol. 1, 16103.

Orivuori, L., Loss, G., Roduit, C., Dalphin, J.-C., Depner, M., Genuneit, J., Lauener, R., Pekkanen, J., Pfefferle, P., Riedler, J., et al. (2014). Soluble immunoglobulin A in breast milk is inversely associated with atopic dermatitis at early age: the PASTURE cohort study. Clin. Exp. Allergy 44, 102–112.

Orndorff, P.E., Devapali, A., Palestrant, S., Wyse, A., Everett, M.L., Bollinger, R.R., and Parker, W. (2004). Immunoglobulin-mediated agglutination of and biofilm formation by Escherichia coli K-12 require the type 1 pilus fiber. Infect. Immun. 72, 1929–1938.

Pace, R.M., Williams, J.E., Järvinen, K.M., Belfort, M.B., Pace, C., Lackey, K.A., Gogel, A.C., et al. (2021). Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19. mBio 12, e03192–20.

Palm, N.W., De Zoete, M.R., Cullen, T.W., Barry, N.A., Stefanowski, J., Hao, L., Degnan, P.H., Hu, J., Peter, I., Zhang, W., et al. (2014). Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 158, 1000–1010.

Pammi, M., Cope, J., Tarr, P.I., Warner, B.B., Morrow, A.L., Mai, V., Gregory, K.E., Kroll, J.S., Mcmurtry, V., Ferris, M.J., et al. (2017). Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis : a systematic review and meta-analysis. Microbiome 5, 31.

Patel, M., Glass, R.I., Jiang, B., Santosham, M., Lopman, B., and Parashar, U. (2013). A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J. Infect. Dis. 208, 284–294.

Penders, J., Stobberingh, E.E., van den Brandt, P.A., and Thijs, C. (2007). The role of the intestinal microbiota in the development of atopic disorders. Allergy 62, 1223–1236.

Perl, S.H., Uzan-Yulzari, A., Klainer, H., Asiskovich, L., Youngster, M., Rinott, E., and Youngster, I. (2021). SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women. JAMA 325 (19), 2013–2014.

Petersen, C., and Turvey, S.E. (2020). Can we prevent allergic disease? Understanding the links between the early life microbiome and allergic diseases of childhood. Curr. Opin. Pediatr. 32, 790–797.

Peterson, D.A., McNulty, N.P., Guruge, J.L., and Gordon, J.I. (2007). IgA response to symbiotic bacteria as a mediator of gut homeostasis. Cell Host Microbe 2, 328–339.

Pröbstel, A.-K., Zhou, X., Baumann, R., Wischnewski, S., Rojas, O.L., Sellrie, K., Bischof, A., Kim, K., Ramesh, A., Dandekar, R., et al. (2020). Gut microbiota-specific IgA+ B cells traffic to the CNS in active multiple sclerosis. Sci. Immunol. 5, 1–26.

Ramanan, D., Sefik, E., Galván-Peña, S., Wu, M., Yang, L., Yang, Z., Kostic, A., Golovkina, T.V., Kasper, D.L., Mathis, D., and Benoist, C. (2020). An immunologic mode of multigenerational transmission governs a gut Treg setpoint. Cell 181, 1276–1290.e13.

Rio-aige, K., Azagra-Boronat, I., Castell, M., Selma-Royo, M., Collado, M.C., Rodríguez-Lagunas, M.J., and Pérez-Cano, F.J. (2021). The breast milk immunoglobulinome. Nutrients 13, 1810.

Rogier, E.W., Frantz, A.L., Bruno, M.E.C., Wedlund, L., Cohen, D.A., Stromberg, A.J., and Kaetzel, C.S. (2014). Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. Proc. Natl. Acad. Sci. USA 111, 3074–3079.

Rognum, T.O., Thrane, S., Stoltenberg, L., Vege, A., and Brandtzaeg, P. (1992). Development of intestinal mucosal immunity in fetal life and the first postnatal months. Pediatr. Res. 32, 145–149.

Roux, M.E., McWilliams, M., Phillips-Quagliata, J.M., Weisz-Carrington, P., and Lamm, M.E. (1977). Origin of IgA-secreting plasma cells in the mammary gland. J. Exp. Med. 146, 1311–1322.

Sbihi, H., Boutin, R.C., Cutler, C., Suen, M., Finlay, B.B., and Turvey, S.E. (2019). Thinking bigger : how early-life environmental exposures shape the gut microbiome and influence the development of asthma and allergic disease. Allergy 74, 2103–2115.

South, M.A., Warwick, W.J., Wolheim, F.A., and Good, R.A. (1967). The IgA system. 3. IgA levels in the serum and saliva of pediatric patients–evidence for a local immunological system. J. Pediatr. 71, 645–653.

Sterlin, D., Fadlallah, J., Adams, O., Fieschi, C., Parizot, C., Dorgham, K., Rajkumar, A., Autaa, G., El-Kafsi, H., Charuel, J.-L., et al. (2020). Human IgA binds a diverse array of commensal bacteria. J. Exp. Med. 217, e20181635.

Tomicić, S., Johansson, G., Voor, T., Björkstén, B., Böttcher, M.F., and Jenmalm, M.C. (2010). Breast milk cytokine and IgA composition differ in Estonian and Swedish mothers-relationship to microbial pressure and infant allergy. Pediatr. Res. 68, 330–334.

Torow, N., Marsland, B.J., Hornef, M.W., and Gollwitzer, E.S. (2017). Neonatal mucosal immunology. Mucosal Immunol 10, 5–17.

Tran, H.Q., Ley, R.E., Gewirtz, A.T., and Chassaing, B. (2019). Flagellin-elicited adaptive immunity suppresses flagellated microbiota and vaccinates against chronic inflammatory diseases. Nature communications 10 (1), 5650.

Trend, S., Strunk, T., Lloyd, M.L., Kok, C.H., Metcalfe, J., Geddes, D.T., Lai, C.T., Richmond, P., Doherty, D.A., Simmer, K., and Currie, A. (2016). Levels of innate immune factors in preterm and term mothers' breast milk during the 1st month postpartum. Br. J. Nutr. 115, 1178–1193.

Verhasselt, V., Milcent, V., Cazareth, J., Kanda, A., Fleury, S., Dombrowicz, D., Glaichenhaus, N., and Julia, V. (2008). Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. Nat. Med. 14, 170–175.

Wang, S., Ryan, C.A., Boyaval, P., Dempsey, E.M., Ross, R.P., and Stanton, C. (2020). Maternal vertical transmission affecting early-life microbiota development. Trends Microbiol 28, 28–45.

Weaver, L.T., Arthur, H.M., Bunn, J.E., and Thomas, J.E. (1998). Human milk IgA concentrations during the first year of lactation. Arch. Dis. Child. 78, 235–239.

Weemaes, C., Klasen, I., Goertz, J., Beldhuis-Valkis, M., Olafsson, O., and Haraldsson, A. (2003). Development of Immunoglobulin A in Infancy and Childhood. Scand. J. Immunol. 58, 642–648.

Wilson, E., and Butcher, E.C. (2004). CCL28 controls immunoglobulin (Ig)A plasma cell accumulation in the lactating mammary gland and IgA antibody transfer to the neonate. J. Exp. Med. 200, 805–809.

Wold, A.E. (1998). The hygiene hypothesis revised: is the rising frequency of allergy due to changes in the intestinal flora? Allergy 53, 20–25.

Wright, P.F., Wieland-Alter, W., Ilyushina, N.A., Hoen, A.G., Arita, M., Boesch, A.W., Ackerman, M.E., Van Der Avoort, H., Oberste, M.S., Pallansch, M.A., et al. (2014). Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J. Infect. Dis. 209, 1628–1634.

Zuurveld, M., van Witzenburg, N.P., Garssen, J., Folkerts, G., Stahl, B., Van't Land, B., and Willemsen, L.E.M. (2020). Immunomodulation by human milk oligosaccharides: the potential role in prevention of allergic diseases. Front. Immunol. 11, 801.